{
  "site": "Biotech411",
  "edition_date": "2026-11-21",
  "stories": [
    {
      "id": "cber-safety-council",
      "title": "FDA forms a safety council to follow biologics after approval",
      "summary": "The council will oversee postmarket safety across CBER products, including cell and gene therapies and blood products.",
      "topic": "Regulatory policy",
      "date": "2026-11-19",
      "source": "FDA",
      "url": "https://www.fda.gov/vaccines-blood-biologics/whats-new-biologics/fda-establishes-cber-safety-council-strengthen-postmarketing-oversight-biological-products"
    },
    {
      "id": "infilbray-gaucher",
      "title": "Infilbray wins approval for neurological symptoms of type 3 Gaucher disease",
      "summary": "FDA cleared venglustat for adults and children weighing at least 15 kg after a study compared it with enzyme replacement therapy.",
      "topic": "Rare disease",
      "date": "2026-11-18",
      "source": "FDA",
      "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease"
    },
    {
      "id": "lembaz-niemann-pick",
      "title": "FDA clears Lembaz for infantile-onset Niemann-Pick type C",
      "summary": "The indication covers reducing mortality risk in patients weighing at least 7 kg whose neurological symptoms began before age six.",
      "topic": "Rare disease",
      "date": "2026-11-17",
      "source": "FDA",
      "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer"
    },
    {
      "id": "rybrevant-head-neck",
      "title": "Rybrevant Faspro gains a head and neck cancer indication",
      "summary": "FDA granted accelerated approval after prior platinum chemotherapy and PD-(L)1 treatment, excluding HPV-associated oropharyngeal tumors.",
      "topic": "Oncology",
      "date": "2026-11-05",
      "source": "FDA",
      "url": "https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and"
    },
    {
      "id": "jemperli-rectal-cancer",
      "title": "FDA grants accelerated approval for Jemperli in a subset of rectal cancers",
      "summary": "The new indication covers adults with stage II or III locally advanced tumors that are MSI-high or mismatch-repair deficient.",
      "topic": "Oncology",
      "date": "2026-10-19",
      "source": "FDA",
      "url": "https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer"
    },
    {
      "id": "gsd-phase-three-results",
      "title": "Glycogen storage disease trial posts its phase 3 results",
      "summary": "The DTX401-CL301 registry record now includes the results tables underlying the program’s evaluation of daily cornstarch intake.",
      "topic": "Trial results",
      "date": "2026-10-14",
      "source": "ClinicalTrials.gov",
      "url": "https://clinicaltrials.gov/study/NCT05139316?tab=results"
    },
    {
      "id": "fayuvi-sanfilippo",
      "title": "Fayuvi gains approval for pediatric Sanfilippo syndrome type A",
      "summary": "The indication covers neurological manifestations in children whose neurodevelopmental function is preserved.",
      "topic": "Rare disease",
      "date": "2026-09-17",
      "source": "FDA",
      "url": "https://www.fda.gov/vaccines-blood-biologics/fayuvi"
    }
  ],
  "records": [
    {
      "id": "rybrevant-faspro",
      "name": "Rybrevant Faspro · head and neck cancer",
      "category": "Oncology",
      "status": "Accelerated approval",
      "summary": "OrigAMI-4 examined amivantamab in head and neck cancer. FDA based the new indication on a group of 102 previously treated patients.",
      "events": [
        {
          "date": "2024-04-22",
          "label": "OrigAMI-4 (NCT06385080) began.",
          "source": "ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT06385080"
        },
        {
          "date": "2026-11-05",
          "label": "FDA granted accelerated approval for eligible adults with recurrent or metastatic disease after platinum and PD-(L)1 therapy.",
          "source": "FDA",
          "url": "https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and"
        }
      ]
    },
    {
      "id": "jemperli",
      "name": "Jemperli · rectal cancer",
      "category": "Oncology",
      "status": "Accelerated approval",
      "summary": "AZUR-1 enrolled patients with previously untreated stage II or III locally advanced rectal cancer with MSI-high or mismatch-repair-deficient tumors.",
      "events": [
        {
          "date": "2023-02-10",
          "label": "ClinicalTrials.gov first posted the AZUR-1 study record (NCT05723562).",
          "source": "ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05723562"
        },
        {
          "date": "2023-04-03",
          "label": "AZUR-1 began enrolling patients, according to the study record.",
          "source": "ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05723562"
        },
        {
          "date": "2026-10-19",
          "label": "FDA granted accelerated approval for the biomarker-defined rectal cancer indication.",
          "source": "FDA",
          "url": "https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer"
        }
      ]
    },
    {
      "id": "genglycos",
      "name": "Genglycos · glycogen storage disease Ia",
      "category": "Rare disease",
      "status": "Accelerated approval",
      "summary": "The DTX401 phase 3 study measured daily cornstarch use. FDA required further evidence of clinical benefit after accelerated approval.",
      "events": [
        {
          "date": "2021-11-08",
          "label": "The phase 3 study DTX401-CL301 (NCT05139316) began.",
          "source": "ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05139316"
        },
        {
          "date": "2026-02-20",
          "label": "The study reached its recorded completion date.",
          "source": "ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05139316"
        },
        {
          "date": "2026-08-19",
          "label": "FDA granted accelerated approval as an adjunct to nutritional management for patients aged eight and older.",
          "source": "FDA",
          "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia"
        },
        {
          "date": "2026-10-14",
          "label": "ClinicalTrials.gov posted the study’s first results tables.",
          "source": "ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT05139316?tab=results"
        }
      ]
    },
    {
      "id": "fayuvi",
      "name": "Fayuvi · Sanfilippo syndrome type A",
      "category": "Rare disease",
      "status": "Approved",
      "summary": "Study NCT02716246 was one of three records FDA cited in its review of Fayuvi for children with preserved neurodevelopmental function.",
      "events": [
        {
          "date": "2016-04-25",
          "label": "The treatment study (NCT02716246) began.",
          "source": "ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/NCT02716246"
        },
        {
          "date": "2026-09-17",
          "label": "FDA licensed Fayuvi to treat neurological manifestations of pediatric Sanfilippo syndrome type A in the indicated population.",
          "source": "FDA",
          "url": "https://www.fda.gov/media/194921/download"
        }
      ]
    }
  ]
}
